August 23, 2020, Coralville, IA – Emmyon is pleased to announce that patent offices in the US, Europe, Canada, Israel and Hong Kong have issued 7 new patents for compositions and/or uses of small molecules including the natural compounds ursolic acid and tomatidine, other recently discovered natural compounds that increase muscle mass, and several recently discovered novel small molecule inhibitors of skeletal muscle atrophy and obesity. These new patents increase Emmyon’s IP portfolio to 27 granted patents in the US, Europe, Canada, Japan, China, Australia, Israel and Hong Kong, with many additional pending patent applications in major markets around the world.
Emmyon scientists discover a novel molecular mechanism of skeletal muscle atrophy
January 17, 2020, Coralville, IA – In collaboration with colleagues at the University of Iowa and the Buck Institute for Research on Aging, Emmyon scientists Scott Ebert and Chris Adams published a new paper today describing a previously unknown mechanism of skeletal muscle atrophy.
The paper, entitled “Activating transcription factor 4 (ATF4) promotes skeletal muscle atrophy by forming a heterodimer with the transcriptional regulator C/EBPβ” was published in the Journal of Biological Chemistry. To view the paper, please click here.
Emmyon receives new patents for ursolic acid in the US and China and new patents for tomatidine in China and Israel
January 2, 2020, Coralville, IA – Emmyon is pleased to announce that the US, Chinese and Israeli patent offices have issued several new patents for uses of ursolic acid and tomatidine. These new patents significantly expand Emmyon’s IP coverage around ursolic acid and tomatidine.
Dr. John Talley named one of world’s 100 most influential people in drug discovery and development
December 1, 2019, Coralville, IA – Emmyon is delighted to announce that its Vice President of Chemistry, Dr. John Talley, has been named again (for the fifth year in a row) to the highly prestigious Power List of The Medicine Maker magazine. The Medicine Maker Power List is comprised of the world’s 100 most influential people in drug discovery and development.
Emmyon appoints seven distinguished scientists to its Scientific Advisory Board
May 20, 2019, Coralville, IA – Emmyon is pleased to announce that seven leading scientists have joined our Scientific Advisory Board, bringing deep expertise and capabilities in drug development, clinical nutrition, skeletal muscle biology, metabolism, obesity, diabetes, aging and translational research. Our new SAB members are Drs. Sue Bodine, Daryl Granner, Peter Snyder, Blake Rasmussen, Bret Goodpaster, Teresa Zimmers, and Andrew Judge. Please see our Scientific Advisory Board page for further information.
Emmyon receives a new Australian patent for ursolic acid and a new European patent for tomatidine
January 11, 2019, Coralville, IA – Emmyon is pleased to announce that the Australian Patent Office has issued a new patent for the use of ursolic acid to increase muscle mass or reduce muscle atrophy, and the European Patent Office has issued a new patent for methods and compositions for treating muscle atrophy, increasing muscle mass and/or enhancing muscle formation using tomatidine. These new patents, which are exclusively licensed to Emmyon from the University of Iowa Research Foundation, significantly expand Emmyon’s IP coverage around ursolic acid and tomatidine. The patents’ lead inventor is Emmyon’s President, Chris Adams, MD, PhD.